I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy maintained a Buy rating on Inmune Bio with an $8 price target. The decision is supported by strengthening Phase 2 MRI data for XPro1595 in early Alzheimer's, showing improvements in brain structure, and a de-risked FDA-aligned registrational path. The absence of ARIA safety events and Fast Track status further justify the positive outlook.
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inmune Bio, retaining the price target of $8.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Jason McCarthy has given his Buy rating due to a combination of factors, starting with the strengthening clinical evidence for XPro1595 in early Alzheimer’s disease. Recent Phase 2 MRI data show meaningful, treatment-related improvements in both white matter integrity and gray matter cortical microstructure, suggesting XPro may impact neural connectivity as well as cognition-driving regions of the brain.
McCarthy also highlights the de-risked, FDA-aligned Phase 2b/3 adaptive registrational program, which uses biomarker-enriched patient selection and well-established cognitive and functional endpoints to maximize the chance of successful approval. The absence of ARIA-related safety events, together with Fast Track status and an unchanged $8 price target, underpins his view that INmune Bio offers an attractive risk-reward profile and justifies maintaining a Buy rating on the shares.
McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Inmune Bio, and AIM ImmunoTech. According to TipRanks, McCarthy has an average return of -10.3% and a 32.80% success rate on recommended stocks.